Latest Conference Articles

Adjuvant ibandronate (Boniva) added to hormone therapy did not provide a clinical benefit to postmenopausal patients with HR-positive, early-stage breast cancer, according to findings from the phase III TEAM IIB trial.

Linda T. Vahdat, MD, PhD, ‎Breast Cancer Research Program Leader at Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian, discusses the ongoing METRIC trial and the potential for glembatumumab vedotin as a treatment for patients with triple-negative breast cancer (TNBC).

The&nbsp;<em>HER2</em>-enriched subtype of HER2-positive breast cancer is a strong predictor of sensitivity to dual HER2 blockade without the use of chemotherapy, according to findings presented&nbsp;at the 2016 San Antonio Breast Cancer Symposium.

Treatment with icotinib more than doubled intracranial progression-free survival (iPFS) compared with whole brain irradiation (WBI) combined with standard chemotherapy.

The addition of an aromatase inhibitor (AI) to pertuzumab (Perjeta) and trastuzumab (Herceptin) improved progression-free survival (PFS) by 3.09 months, when compared with trastuzumab plus an AI, according to findings from the phase II PERTAIN trial.

Osimertinib (Tagrisso) reduced the risk of disease progression by 70% compared with a chemotherapy doublet in patients with EGFR T790M-mutant non&ndash;small cell lung cancer (NSCLC) who progressed after first-line targeted therapy, according to phase III clinical trial results.

​The addition of the veliparib to carboplatin/paclitaxel demonstrated promising objective response rates and trends toward improvements in progression-free survival and overall survival in patients with advanced&nbsp;<em>BRCA</em>-positive breast cancer.

Extending treatment with letrozole by an additional 5 years after 5 years of successful treatment did not improve disease-free survival or overall survival in postmenopausal women with early-stage hormone receptor -positive breast cancer.

Adding everolimus to fulvestrant reduced the risk of progression or death by 40% compared with fulvestrant alone for postmenopausal patients with metastatic HR-positive, HER2-negative breast cancer who are resistant to aromatase inhibitor therapy.

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program, Stanford Women&rsquo;s Cancer Center, co-director of Molecular Therapeutics Program, Stanford Medicine, discusses the phase III SOPHIA trial, which is exploring margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in the treatment of patients with HER2-positive breast cancer.

Roy. S. Herbst, MD, PhD, professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center, discusses the phase III KEYNOTE-010 study, in which pembrolizumab provided superior overall survival over docetaxel in patients with previously treated, PD-L1-expressing advanced non-small cell lung cancer. He discussed these results during an interview at the IASLC 17th World Conference on Lung Cancer.

Ropeginterferon alfa-2b is noninferior to hydroxyurea in terms of complete hematologic response for the treatment of polycythemia vera, and has the advantage of being a safer and more tolerable therapy.

Alex Herrera, MD, assistant professor, City of Hope, discusses a study investigating the use of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in the treatment of relapsed or treatment-resistant Hodgkin lymphoma during the American Society of Hematology (ASH) Annual Meeting.

Early data from a phase I/II study suggest that the combination of brentuximab vedotin and nivolumab may be an active and well-tolerated outpatient regimen in patients with relapsed/refractory classical Hodgkin lymphoma after failure of standard frontline chemotherapy.

Two-thirds of patients with chronic lymphocytic leukemia that progressed on B-cell receptor pathway inhibitors had objective responses to treatment with venetoclax (Venclexta), results of a small open-label trial showed.

Treatment with the CD19-directed CAR T-cell therapy KTE-C19 showed a complete remission rate of 73% for patients with aggressive, chemorefractory primary mediastinal B-cell lymphoma and transformed follicular lymphoma, according to findings from the multicenter phase II ZUMA-1 study.

Kathryn Kolibaba, MD, associate chair of hematology research program, US Oncology, discusses an ongoing phase 2 study of brentuximab vedotin (Adcetris) with as frontline therapy in patients with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).<br /> &nbsp;

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase II trial combining nivolumab (Opdivo) with ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL) and richter transformation (RT) during the American Society of Hematology (ASH) Annual Meeting.<br /> &nbsp;

Treatment with enasidenib (AG221) was active and was well tolerated in pretreated patients with IDH2-mutated myelodysplastic syndrome, including those who failed hypomethylating agents, according to findings from a phase I/II study.

Combination induction therapy with ibrutinib (Imbruvica) and obinutuzumab (Gazyva) after bendamustine debulking induced a 100% response rate in patients with chronic lymphocytic leukemia (CLL), according to findings from the phase II CLL2-BIG trial.&nbsp;

The combination of lirilumab and azacytidine was well tolerated and showed early signals of activity in heavily pretreated patients with acute myeloid leukemia (AML), according to phase Ib/II findings presented at the 2016 ASH Annual Meeting.

Lenalidomide as maintenance following first-line immunochemotherapy substantially improves progression-free survival in the treatment of patients with high-risk chronic lymphocytic leukemia (CLL), according to interim analysis of the phase III CLLM1 study.

Findings from the longest follow-up to date evaluating up to 5 years of ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) show that the agent is safe and effective.

Combining obinutuzumab (Gazyva) with chemotherapy in the first-line setting reduced the risk of disease progression or death by 34% versus rituximab (Rituxan) plus chemotherapy in patients with follicular lymphoma, according to findings from the phase III GALLIUM study.

Pembrolizumab (Keytruda), pomalidomide (Pomalyst), and dexamethasone had an objective response rate of 65% and a very good partial response or better rate of 29% for patients with relapsed/refractory multiple myeloma, according to phase II findings presented at the 2016 ASH Annual Meeting.

Data from a prospective assessment of minimal residual disease from the phase III CASTOR and POLLUX studies demonstrated at least a 3-fold increase in conversion to negative MRD status with the addition of daratumumab (Darzalex) to standard-of-care regimens in the treatment of patients with relapsed/refractory multiple myeloma.

Jeffrey Jones, MD, MPH, associate professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the benefits of venetoclax in chronic lymphocytic luekemia (CLL).

Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses the efficacy seen with venetoclax in multiple myeloma during the ASH Annual Meeting 2016.

With treatment for newly diagnosed acute myeloid leukemia remaining essentially unchanged over the last 4 decades, researchers are hopeful that the addition of the investigational agent vadastuximab talirine to standard 7+3 induction therapy may improve survival for these patients.&nbsp;